NASDAQ:FOLD

Amicus Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy FOLD

*Your capital is at risk

$14.49

+0 (+0%)

At Close: Jun 03, 2026

Amicus Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -100.00. In total, the insiders bought 0 and sold 6.53M FOLD shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-100.00
● Buy	0 shares
● Sell	6.53M shares
0% Buy Activity Strong Negative Correlation
Sell Signal High Confidence Apr 27, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -100. Partially supported by a negative historical correlation. Confidence increased due to high data reliability score of 100. Supported by overwhelming sell-side pressure (0% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Apr 27, 2026 Sell	Common Stock D-Return	Raab Michael Director	Director	115 857 Value: $1.68M
Apr 27, 2026 Sell	Stock Options (right to buy) D-Return	Roberts Eiry Director	Director	42 467 Value: $436.1K
Apr 27, 2026 Sell	Stock Options (right to buy) D-Return	Roberts Eiry Director	Director	30 474 Value: $384.6K
Apr 27, 2026 Sell	Stock Options (right to buy) D-Return	Roberts Eiry Director	Director	45 423 Value: $388.4K
Apr 27, 2026 Sell	Stock Options (right to buy) D-Return	Roberts Eiry Director	Director	40 625 Value: $435.1K
Apr 27, 2026 Sell	Common Stock D-Return	Roberts Eiry Director	Director	76 275 Value: $1.11M
Apr 27, 2026 Sell	Stock Options (right to buy) D-Return	Sblendorio Glenn Director	Director	74 872 Value: $446.2K
Apr 27, 2026 Sell	Stock Options (right to buy) D-Return	Sblendorio Glenn Director	Director	42 467 Value: $436.1K
Apr 27, 2026 Sell	Stock Options (right to buy) D-Return	Sblendorio Glenn Director	Director	30 474 Value: $384.6K
Apr 27, 2026 Sell	Stock Options (right to buy) D-Return	Sblendorio Glenn Director	Director	45 423 Value: $388.4K
Apr 27, 2026 Sell	Stock Options (right to buy) D-Return	Sblendorio Glenn Director	Director	36 111 Value: $386.7K
Apr 27, 2026 Sell	Stock Options (right to buy) D-Return	Sblendorio Glenn Director	Director	18 574 Value: $237.9K
Apr 27, 2026 Sell	Stock Options (right to buy) D-Return	Sblendorio Glenn Director	Director	19 473 Value: $233.7K
Apr 27, 2026 Sell	Stock Options (right to buy) D-Return	Sblendorio Glenn Director	Director	16 236 Value: $139.6K
Apr 27, 2026 Sell	Stock Options (right to buy) D-Return	Sblendorio Glenn Director	Director	20 000 Value: $134.2K
Apr 27, 2026 Sell	Common Stock D-Return	Sblendorio Glenn Director	Director	142 564 Value: $2.07M
Apr 27, 2026 Sell	Stock Options (right to buy) D-Return	Whitman Burke W Director	Director	74 872 Value: $446.2K
Apr 27, 2026 Sell	Stock Options (right to buy) D-Return	Whitman Burke W Director	Director	30 474 Value: $384.6K
Apr 27, 2026 Sell	Stock Options (right to buy) D-Return	Whitman Burke W Director	Director	25 964 Value: $311.6K
Apr 27, 2026 Sell	Common Stock D-Return	Whitman Burke W Director	Director	118 598 Value: $1.72M
Apr 27, 2026 Sell	Stock Options (right to buy) D-Return	Mcglynn Margaret G Director	Director	74 872 Value: $446.2K
Apr 27, 2026 Sell	Stock Options (right to buy) D-Return	Wheeler Craig A Director	Director	42 467 Value: $436.1K
Apr 27, 2026 Sell	Stock Options (right to buy) D-Return	Wheeler Craig A Director	Director	30 474 Value: $384.6K
Apr 27, 2026 Sell	Stock Options (right to buy) D-Return	Wheeler Craig A Director	Director	45 423 Value: $388.4K
Apr 27, 2026 Sell	Stock Options (right to buy) D-Return	Wheeler Craig A Director	Director	36 111 Value: $386.7K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT AMICUS THERAPEUTICS

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzym...

Read Full Profile Here